The purpose of the present study is to visual ize and quantify dopamine D2 receptors in the living hu man brain using an 123I-labeled ligand and the single pho ton emission computerized tomography (SPECT) tech
nique. S-( -)-Iodobenzamide [S-( -)-IBZMJ has been
shown to be a highly selective ligand with high affinity for D2 receptors in experimental studies, Five millicuries (185 MBq) of mI-labeled S-( -)-IBZM was administered intravenously to 12 control subjects, 22 parkinsonian pa tients under L-Dopa therapy, 12 parkinsonian patients without L-Dopa, \0 unmedicated patients with Hunting ton's disease, and 12 patients under different neurolep tics. Data collection with a rotating double-head scintil lation camera started 1 h after injection and lasted for 50 min. In a semiquantitative approach, a ratio was calcu lated between mean counts per pixel in the striatum and a region in the lateral frontal cortex, which was 1. 74 ± 0.10 in the control group. A marked reduction of this ratio was found in patients with Huntington's disease (1.38 ± 0.12; p = 0.000l), no significant changes in untreated parkinDopamine receptors play an important role in the treatment of various neuropsychiatric disorders such as Parkinson's disease, Huntington's disease, and schizophrenia. In the case of schizophrenia they might even be involved in pathogenesis. Since the first report of in vivo imaging of dopamine re ceptors in humans by Wagner and co-workers (1983) , this topic has been the subject of increasing research interest. Such studies use the positron sonian patients (1.67 ± 0,14), but a reduction in L Dopa-treated cases (1.59 ± 0,\3; p = 0.0014). A curvi linear relationship was found between total daily dose of neuroleptics and the reduction of this ratio. Estimated receptor blockade under full neuroleptic treatment was
75-80%. S-( -)-IBZM binding was reduced with increas
ing age (p < 0,0 I). Specific binding was reduced markedly when the racemic mixture of IBZM was used, and no specific binding was seen with the R-( + i-isomer, demon strating the stereoselectivity of IBZM binding, The re sults show that dopamine D2 receptors can be clearly visualized with high resolution using the SPECT tech nique and S-( -)-IBZM as a ligand. A semiquantitative approach can give estimates for receptor blockade or re ceptor density, This method is of clinical value for the diagnosis of degenerative neurological disorders such as Huntington's disease and for the monitoring of neurolep tic treatment. Key Words: Dopamine receptors Huntington's disease-N euroleptics-Parkinson' s dis ease-Single photon emission computerized tomography.
emISSIOn tomography (PET) technique and dopa mine antagonists labeled with positron-emitting iso topes as tracers (Welch et a!. , 1983; Maziere et aI., 1984; Farde et aI. , \986) , Although PET still is the "gold standard" for these kinds of imaging studies, this technique is limited to a relatively small number of research centers, requires an on-line cyclotron facility, and can hardly be used for clinical routine so far. Single photon emission computerized tomog raphy (SPECT) is more available and uses tracers labeled with gamma-emitting isotopes with longer half-life, which can be shipped from the place of synthesis and do not have to be synthesized on-line. Therefore, this technique is more practical for clin ical applications,
We were interested in the use of a new 1231_ labeled ligand for dopamine D2 receptor imaging in SPECT, a benzamide derivative, iodobenzamide {S-( -)-N-[(l-ethyl-2-pyrrolidinyl)methyl]-2-hy droxy-3-iodo-6-methoxybenzamide; S-( -)-IBZM}. This substance belongs to the benzamide class of neuroleptics and has been shown to bind with high specificity and high affinity to dopamine D2 recep tors (Briicke et aI., 1988; Kung et aI. , 1988b) . Spip erone derivatives, which are often used for PET studies, are less specific and also bind to serotonin S2 receptors (Farde et aI. , 1985) . Another advan tage of benzamides is their binding reversibility, which makes it possible to perform in vivo measure ments at equilibrium (Farde et aI., 1986) .
The aim of the present study is to examine the potency of 1 2 3 1-labeled S-( -)-IBZM for dopamine D2 receptor imaging and quantification with SPECT in patients with extrapyramidal disorders and in pa tients under neuroleptic treatment.
METHODS

Synthesis of [1231]S_( -)-IBZM
s-( -)-and R-( + )-IBZM were synthesized by a modi fication of the method described by dePaulis et at. (1985) . Electrophilic iodination was performed with [123I]Nal (0.08 nmol/mCi), using peroxyacetic acid as oxidant and 0.01 M HCl as solvent. The reaction was performed at 50°C for 10 min and the whole reaction mixture (150 f.Ll) was injected onto a preparative HPLC column.
[1231]S_ (-)-lBZM was separated from the reaction mixture; the eluate containing the product peak was evaporated, re dissolved in a small volume of ethanol, diluted with phos phate-buffered saline, and filtered through sterile one way membrane filters.
The radiochemical purity of the product was >97% and the in vitro stability» 8 h. Theoretical specific activity is > 10,000 Ci/mmol and the 1251 content is <0.6%. Table) shows the numbers, mean age, and age range of patients in the different groups, who were examined with the S-( -)-IBZM isomer. The control group consisted of volunteers or patients with peripheral neurological prob lems. Patients with Parkinson's disease were divided into a group treated with L-Dopa and/or dopamine agonists and patients without such treatment. The stage of the disease varied between stage I and IV (according to Hoehn and Yahr) . Patients with Huntington's disease were untreated. The group treated with neuroleptics con sisted mainly of psychotic patients (schizophrenic or manic), who received different neuroleptics at different doses, mostly in combination. Among others, haloperi dol, chlorprothixene, levomepromazine, thioridazine, clopenthixol, and sulpiride were used. One patient re ceived lev orne promazine because of chronic pain and an other a low dose of flupenthixol because of depressive symptoms. After blockade of thyroid uptake, subjects re ceived 5 mCi (185 MBq) bolus i. v. of 1231-labeled S-( -) lBZM.
Patients and controls
To determine the stereo selectivity of lBZM binding, five controls, two patients with Parkinson's disease, one with Huntington's disease, and one under neuroleptic treatment, were studied with the racemic mixture of 1231 _ labeled S-( -)-and R-( + )-IBZM. Two parkinsonian pa tients were examined with the S-( -)-and the R-( + ) isomers on two different occasions.
Data collection
A dual-head rotating scintillation camera (Siemens Dual Rota ZLC37) connected to a dedicated computer system (Nodecrest Micas 2000) was used for SPECT. To determine the best time frame for data collection, a dy namic study was performed in a normal volunteer with 10 scans, each with a 20-min rotation, starting immediately after injection. For this study a high-sensitivity collimator was used to obtain higher count rates. Results showed that the specific binding [average counts/pixel striatal re gion of interest (RO!) minus average counts/pixel fronto lateral cortical ROI; Fig. ) ] in the striatum reached a max imum at �40 min post injection and remained stable up to 2 h (Fig. 2) . Therefore, the time between 60 and ) 10 min from the total activity in the striatum (top), the striatal activity, which is due to specific S-( -)-iodobenzamide binding, is ob tained (bottom).
post injection was chosen for data collection for all other studies. For these the camera heads were equipped with low-energy-all-purpose collimators (full width at half maximum 14 mm in the transverse plane). The scanning modalities and image processing have been described in detail (Podreka et aI., 1984 (Podreka et aI., , 1989 ; therefore, only a brief description is given here. The subjects were placed on a reclining dentist's chair with a special head support, which enabled the reduction of the rotation diameter to 28 cm. Sixty projections (2 x 30 angles; 100 s/angle) with a sampling distance of 3.125 mm were achieved. Projec tions were filtered with a filter of variable shape and size (Todd Pokropek et aI., 1982) for reduction of poisson noise (King et aI., 1984) , and data were reorganized in a sinogram. After attenuation correction (Bellini et aI., 1979) , 3. 125-mm-thick cross sections were reconstructed by filtered back-projection in 128 x 128 matrices. Con secutive summation of five sections gave a set of 15.6-mm-thick transverse slices. From these one slice was chosen where the striatum was best visualized and one
where the cerebellum was seen. ROls were drawn in the left and right striatum, in the left and right frontolateral cortex (Fig. 1) , and in both cerebellar hemispheres by one and the same examiner. Mean counts per pixel were calculated in these regions and ratios performed between striatal and frontal cortex mean values and striatal and cerebellar counts .
Calculation of dose-response curve in patients under neuroleptics
The total daily dose of neuroleptics per kilogram body weight was transformed into a chlorpromazine equiva lence dose (activity of chlorpromazine = 1), according to Haase (1972) . The percentage of unoccupied receptors was calculated by dividing the measured ratio of [12311S_( -)-IBZM binding in striatum/frontal cortex di minished by I, by the age-corrected control ratio dimin ished by 1, times 100. The age-corrected control ratio was calculated by interpolating the values obtained in controls according to the age of the patient studied, using the lin ear regression of age and striatum/frontal cortex ratios.
Statistical evaluation
Student's t test for unpaired samples (two tailed) and correlation-regression analysis were used. Figure 2 shows the time-activity distribution in striatum, frontolateral cortex, and cerebellum in one normal volunteer after an intravenous injection of 5 mCi (185 MBq) [ 123 IJS-( -)-IBZM. By subtract ing the nonspecific activity in the frontolateral cor tex from the total activity in the striatum (top), the striatal activity, which is due to specific S-( -) IBZM binding, can be obtained (bottom). This spe cific binding reaches a plateau at �40 min, which remains stable up to 2 h. Washout of specific bind ing is seen after 2 h, which underlines the revers ibility of S-( -)-IBZM binding.
RESULTS
Kinetic study
Age dependency
An age dependency of e 2 3 I]S-( -)-IBZM binding in the control group is seen, with a decrease of the striatum/frontal cortex ratio with increasing age (r = 0. 763, p < 0.01, two-sided correlation regression analysis; Fig. 3 ).
Parkinson's disease, Huntington's disease, and neuroleptic treatment Stereoselectivity. In Fig. 4 the striatal/frontal cor tex ratios of [ 123 I]S_( -)-IBZM binding in the con trol group are compared with ratios in parkinsonian patients with and without L-Dopa treatment, in pa tients with Huntington's disease, and in patients treated with different neuroleptics. Whereas un treated parkinsonian patients do not differ from the control group (controls: 1.74 ± 0.10; patients: 1.67 ± 0.14; mean ± SD, NS), patients with Parkinson's 1.2 y = 2,0027 -4,8865e-3x R = 0,763 P < 0,01
disease on L-Dopa or dopamine agonists show a significantly lower ratio (1. 59 ± 0. 13; p = 0. 0014). However, the first group does not differ signifi cantly in age from the controls (controls: 53.0 ± 15 .7 years; untreated patients: 58.6 ± 12. 6 years), whereas the latter is significantly older (treated pa tients: 63. 2 ± 11. 3 years; p = 0. 044).
A markedly lower ratio is measured in patients with Huntington's disease (1. 38 ± 0. 12; p = 0. 0001) and in patients on different neuroleptics (1. 37 ± 0.21; p = 0.0001) (see also Fig. 5 ). • S( -)IBZM Compared with the control 121 IBZM Racema te group (n = 12), significantly lower ratios are measured in parkinsonian patients on L Dopa or dopamine agonists (n = 22) and markedly reduced ra tios in patients with Hunting ton's disease (n = 10) and psy chotic patients under neurolep tic treatment (n = 12). No difference is seen in untreated parkinsonian patients (n = 12). Mean ± SO, *p < 0.01, ***p weight (as calculated with a dose equivalence factor for different neuroleptics, which are "normalized" to the potency of chlorpromazine), a curvilinear dose-response relationship is found, which is highly significant (p < 0.01). The only two values that do not fit this correlation are obtained from patients treated with sulpiride (Fig. 6 ).
DISCUSSION
To our knowledge this is the first report on neu roreceptor imaging with SPECT in a broader cIini- To allow an interindividual com parison, pixel counts were converted to ratios between pixel counts and average counts in a frontolateral region of interest. The four images are scaled to the maximal ratio, which was ob tained in the normal control. Binding in the par kinsonian patient is still within the normal range, whereas a marked reduction is seen in Huntington's disease, despite the fact that no morphological abnormalities in computed to mography or magnetic resonance were de tected in this case. In a patient treated with 25 mg haloperidol orally, S-( -)-IBZM binding in the striatum was blocked, indicating a suffi ciently high therapeutic dose.
cal application. Although there is rapidly growing interest in the use of SPECT for receptor studies in the human brain, only preliminary reports have been published so far on this subject. Our results show that dopamine D2 receptors in the striatum can be visualized with [I2 3 I]S-( -)-IBZM and SPECT with high resolution, good contrast, and an image quality comparable to that of PET. Crawley et al. (1986) had reported on the use of 12 3 1-labeled IBZM for dopamine receptor imaging with SPECT in a normal human volunteer in a pre liminary study. Synthesis and biodistribution of this
Neuroleptics (daily dose mg/kg, Cpz equivalents) ligand in rats have been described in detail by Kung et aI. (l988a) . The pharmacological characterization of 5-( -)-IBZM in membrane binding studies and in in vitro autoradiography showed the high selectivity and high affinity for dopamine D2 receptors (Brucke et aI. , 1988; Bruck et aI. , 1989; Kung et aI. , 1988b) . Ex vivo autoradiographical studies in rats and mice proved that 5-( -)-IBZM crosses the blood-brain barrier, binds to areas in the brain known to have high concentrations of dopamine D2 receptors, and showed that this binding can be blocked by pretreatment of these animals with D2 antagonists (Kung et aI. , 1988a; Singhanyom et aI. , 1988) or D2 agonists (Singhanyom et aI. , 1988) . Do simetric studies in normal volunteers give estimates of radiation dose and show that the application of 5 mCi (185 MBq) of the 1231-labeled substance is safe (Velchik et aI. , 1989) . The most recent study reports a whole-body radiation dose of 26 mrad/mCi and a dose of 776 mrad/mCi to the lower large intestine as the critical organ (Alavi et aI. , 1990) . All these stud ies provided the basis for the use of 1231-labeled
The results of our kinetic study with a series of 10 SPECT scans from 0 to 200 min after the injection of 5 mCi (185 MBq) of [1231]5_( -)-IBZM show that the amount of specifically bound ligand in the stri atum reaches a maximum after �40 min and that a near-equilibrium exists for up to � 120 min. These results are in good agreement with data from PET studies, obtained with IIC-labeled raclopride, an other benzamide, where an equilibrium of specific binding was also found (Farde et aI., 1986) . This and the decline of specific binding after 2 h are due to the reversibility of 5-( -)-IBZM binding, which has also been described in in vitro binding experiments (Brucke et aI., 1988) . Thus, a time between 60 and 110 min was chosen for the SPECT imaging. For the calculation of specific binding in the kinetic study, the activity in a region of the dorsolateral frontal cortex or the cerebellum was subtracted from the total activity in the striatum. It was assumed that the activity in the dorsolateral frontal cortex or in the cerebellum reflects the free and nonspecifically bound ligand fraction (Farde et aI., 1986) . The cer ebellum has been shown to contain only few dopamine D2 receptors (Bouthenet et aI. , 1987) . Our own results with in vitro autoradiography of 1 2 5 I-Iabeled 5-( -)-IBZM in mice, rats, and mon keys did not show specific binding of this ligand in frontal cortex or cerebellum (T. Brucke et aI. , un published results). Also in PET studies with [ ll C]raclopride as ligand, it was shown that the frontal cortex does not contain a considerable amount of dopamine D2 receptors (Farde et aI. , 1988b) . Thus, the use of both areas as "nonspe cific" reference regions seemed justified. However, in the present study, the cerebellar region some times seemed to give too low counts, resulting in apparently overestimated specific binding in the striatum and a wider variation of the results. That the cerebellum might not be an ideal region for this purpose, because its nonspecific binding might be lower than the nonspecific binding in the striatum, has recently also been suggested by P. Seeman (per sonal communication at the seminar on receptor binding radiotracers at the 36th Society of Nuclear Medicine meeting, 1989). We therefore used the dorsolateral frontal cortex as reference region and, with the exception of the kinetic data, we expressed the results of our present study as ratio of striatum to (dorsolateral) frontal cortex. By using this ratio instead of the subtraction, intersubject variability can be reduced. Because measurements are made at near-equilibrium, this ratio should provide a semi quantitative index for Bma)Kd (Baron, 1988) .
Our data demonstrate the stereoselectivity of IBZM binding with a reduction of the specific bind ing to about one-half when the racemic mixture of IBZM is used and a disappearance of any specific binding with the R-( + )-isomer. The reduction of the striatum/frontal cortex ratio to I in the studies with the R-( + )-isomer also validates the use of this in dex.
The results of the control group show a signifi cant decrease of [1231] 5-( -)-IBZM binding with a reduction of the striatum/frontal cortex ratio with increasing age. Similar findings have been reported from PET studies (Wong et aI. , 1984; Baron et aI. , 1986) , but controversies exist in postmortem brain analyses (Guttman et aI. , 1986; Morgan et aI., 1987; Palacios et aI., 1988) .
In patients with Parkinson's dise a se not treated with L-Dopa or dopamine agonists, IBZM binding is normal, providing evidence that dopamine D2 re ceptors are usually intact in this disease, but giving no evidence for a receptor supersensitivity. These results do not exclude minor changes of receptor density, which might occur in subregions of the putamen. In a recent publication Rinne and co workers (1990) report an increase in [ ll C]raclopride binding contralateral to the affected side in hemi parkinsonian patients, when left and right striatum was compared. However, these differences are rel atively small and could probably not be detected in comparison with a normal control group. Similar findings have also been observed in some untreated hemiparkinsonian patients in the present study, but these results were not consistent in all cases. Sev eral facts could account for the finding of a reduced binding in parkinsonian patients treated with L-Dopa or dopamine agonists. First, this could be due to a dopamine D2 receptor down-regulation by this ther apy. Second, the patients with Parkinson's disease under L-Dopa therapy were older than the controls, which could be the reason for this reduction. How ever, when the control numbers were age corrected (1.69 instead of 1.74), there was still a difference. Third, there could be some competition between an increased synaptic concentration of dopamine brought about by the L-Dopa therapy or dopamine agonists still present at the time of the examination and IBZM for dopamine D2 receptor binding. Fourth, some evidence exists that there might be a loss of postsynaptic structures in the striatum in later stages of Parkinson's disease, leading to a loss of dopamine receptors and explaining the loss of L-Dopa efficacy (McNeill et ai., 1988) . In a PET study using [ ll C]N-methylspiperone, Hagglund and co-workers (1987) did not find overall differences in dopamine receptor densities in a group of six par kinsonian patients; however, a tendency toward higher densities was observed in earlier stages of the disease.
Our data show that patients with Huntington's disease have a marked reduction of the striatum/ frontal cortex ratio. This is probably due to the loss of striatal neurons, which bear dopamine D2 recep tors. In some of the patients examined, this reduc tion is already seen, when morphological abnormal ities, as studied with CT or magnetic resonance scans, are still absent. This could provide means for early detection of this disease, perhaps even in a preclinical stage. A reduction in striatal D2 receptor density in Huntington's disease has also been sug gested from two earlier PET studies (Leenders et ai., 1986; Hagglund et ai., 1987) and is consistent with postmortem human brain findings (Cross and Rossor, 1983) .
That these SPECT measurements and our semi quantitative approach actually give an index for dopamine D2 receptor density or occupancy by dopamine antagonists is clearly demonstrated by the relationship of the daily oral dose of different neuroleptics and the reduction of the striatum/ frontal cortex ratio (Fig. 6) . Data from two patients that had received 400 and 600 mg sulpiride daily do not fit this dose-response curve. This might indicate either a wrong dose equivalent factor for the calcu lation of the chlorpromazine equivalent for sulpir ide, or it might be due to a nonparallelism between clinically effective doses of sulpiride and dopamine
D2 receptor blockade in the striatum. Sulpiride is considered an atypical neuroleptic with a low fre quency of extrapyramidal side-effects, and it has been suggested that it might bind preferentially to limbic dopamine receptors (Borison et ai., 1983) . However, data from Farde and co-workers (1988a) indicate a similar rate of receptor occupancy in the striatum of patients treated with sulpiride or classi cal neuroleptics.
The dose-response relationship shows a steep de crease in the ratio at relatively low doses, which means that a high degree of receptor occupancy is reached already with such low neuroleptic doses (for example, 0. 5 mg flupenthixol orally). This has to be kept in mind in view of the fact that it is widespread clinical practice to give neuroleptics for sleep disturbances, even in patients with Parkin son's disease. In these patients such a reduction in available dopamine D2 receptors is likely to cause a deterioration of motor function. On the other hand, this curve points out why a further increase of neu roleptic dose, after a certain degree of receptor oc cupancy has been reached, will not change this de gree of occupancy to a large amount. This also ex plains the uselessness of giving excessively high doses of neuroleptics, which has been shown in sev eral clinical studies (Baldessarini et ai., 1988) . The observation that the total daily dose of neuroleptic agents producing extrapyramidal side-effects in half of the patients examined is � 350 mg/day (ED 5 o in chlorpromazine equivalents) (Keepers et ai., 1983) fits well with our data, from which a receptor oc cupancy of 64% can be calculated at that dose. One can easily imagine that about two-thirds of the re ceptors have to be occupied before extrapyramidal symptoms occur. This dose also seems to be similar to the ED 5 0 for the acute antipsychotic benefit of neuroleptics (Baldessarini et ai., 1988) . Our findings are also supported by the results published by Cam bon and co-workers (1987) . These authors found a dose-dependent reduction of the striatum/cerebel lum ratio by various doses and types of neuroleptics with [ 66 Br]bromospiperone in PET, which is almost identical to the dose-response curve in the present study. A similar curvilinear relationship has been reported between haloperidol plasma levels and re ceptor availability as measured with e S F]N-methyl spiperone in PET (Wolkin et ai., 1989) .
In conclusion, our data show that IBZM SPECT is suitable for estimating dopamine D2 receptor densities in degenerative neurological disorders, sometimes facilitating clinical diagnosis (Hunting ton's disease). As an "in vivo dopamine receptor assay," it also seems to be a powerful tool for mon-itoring and optimizing neuroleptic treatment in psy chotic patients, which might be superior to plasma drug measurements.
